Polydex Pharmaceuticals Story Overview

POLXF -- USA Stock  

USD 1.09  0.03  2.68%

Macroaxis News
  
By David Taylor

The industry average is where I look to next to determine where this stock should be in relation to they earnings potential.  This company is trading at 6.83 times earnings.  The industry and sector averages, respectively, are trading at 64.14 times and 63.11 times earnings.  This stock is trading at 1/10th the industry average despite positive earnings and increasing earnings growth.  

Given the EPS ratio, if the company were to be trading at .5 the industry average, 30-times EPS, the stock would be trading at $15.00 per share, a nearly 1,000 percent return.  Keep in mind that only gets the stock up to half the industry average.  

Polydex Pharma is trading at 110 the industry average offering a huge bargain with positive earnings

Polydex Pharma is trading at 1/10 the industry average offering a huge bargain with positive earnings.  Over the past many years earnings have been positive and increasing.  And, yet, the stock is trading at a single-digit EPS ratio.  Whereas the industry average is 65-times earnings, this pharmaceutical company is trading at 6-times earnings.  This is a tremendous opportunity.  




Polydex Pharmaceuticals is mostly a veterinary pharmaceutical company.  The develop, manufacture and distribute their products worldwide.  They are a smaller company with a market capitalization of only $6.2 million.  Their share price is $1.70 per share.  

The pet industry is a $15 billion per year sector.  Of that, there is a large percentage that goes towards health care from either veterinary visits and treatments.  Americans, and more increasingly the rest of the world, spend a considerable amount of money on their pets.  

Earnings-per-share gives a strong indication of what a company will be earning in the future, although this is not a certainty; it is only an indication.  If earnings-per-share are increasing over a given period, say five years, then the indication is that the company will continue to increase their earnings in the next year.  

In the case of POLXF, their earnings have been increasing over the latest few years, as this listing shows:

2012:  -$0.13  

2013:   $0.22  

2014:   $0.20  

2015:   $0.50 

The first thing you might see is that earnings for the previously complete year are on $0.50 in 2015.  Earnings are slated to rise above that for 2016.  But, how much does it cost to “earn” that next year’s earnings?  As mentioned above, only $1.70 per share.  Given all the variables, if the share price remained exactly the same while simultaneously the earnings remained the same, you would “earn” 29% for the year.  I am having a difficult time locating a better return on an annual basis than that.  That is an astronomically high earnings ratio.  

The industry average is where I look to next to determine where this stock should be in relation to they earnings potential.  POLXF is trading at 6.83 times earnings.  The industry and sector averages, respectively, are trading at 64.14 times and 63.11 times earnings.  This stock is trading at 1/10th the industry average despite positive earnings and increasing earnings growth.  

Given the EPS ratio, if the company were to be trading at 1/2 the industry average, 30-times EPS, the stock would be trading at $15.00 per share, a nearly 1,000 percent return.  Keep in mind that only gets the stock up to half the industry average.  

Another key variable that I find compelling about this company is its Inventory Turnover Ratio.  It leads the industry 3.79 versus 2.70.  It sells more of its inventory at a higher pace and a higher margin ratio.  This shows how effective management is at its job of returning value to investors.  And, yet, the stock is priced so low.  

Another point I wanted to show was the gross profit margin versus the industry.  POLXF earns slightly more than double the industry average, 22.8 percent versus 11.5 percent, respectively.  The company not only sells its inventory at a faster rate it also earns more in margins per sale.  

The economy itself is expanding throughout the world.  This will give POLXF the opportunity to expand its sales and continue to grow as a company.  The overall stock market is trading at 25 times earnings on average.  At some point, investors are going to start looking for increased value from earnings potential.  A company like POLXF is exactly that opportunity.  There is so much potential value in a stock priced so discounted to the industry and its own earnings.  

There are very few bargains in the market at this point. However, POLXF is far more than a bargain.  This is a bargain that is beyond difficult to pass.  Add this stock to your portfolio and hold this for a very long period.  You will be glad you did.  

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for Polydex Pharmaceuticals

over a month ago at http://www.nasdaq.com 
CORRECTION Polydex Pharmaceuticals Provides Year End Financial Report
nasdaq News
NasdaqFull coverage
over two months ago at http://healthcaretrends24.com 
Dextran EMEA Market Size, Growth, Research, Applications, Shares Insights for ...
news
Healthcare TrendsFull coverage
over three months ago at http://nlrnews.com 
Polydex Pharmaceuticals Ltd. OTC Runner in Focus
news
Polydex Pharmaceuticals Ltd. has been getting interest from investors after the stock price touched 1.26 at the conclusion of the most recent trade.
over three months ago at http://nlrnews.com 
Polydex Pharmaceuticals Ltd. Shares Are Making Moves
news
Polydex Pharmaceuticals Ltd. has been in the news after the price of the stock hit 1.2 at the conclusion of the most recent close.
over three months ago at http://journalismday.com 
Global Dextran Market Growth by 2022 Herbon, Meito Sangyo, Polydex ...
news
Journalism Day - Jan 11, 2018 Leading players involved in the global Dextran market includes Lukee Bio-Tech, Polydex Pharm, Pharmacosmos, Tianxiangyuan, Shanghai Huamao, LandP Food Ingredient, DSM, Meito Sangyo, Biotec BetaGlucans, LB Nature, Tate and Lyle and Herbon.
over three months ago at http://dailyassessment.com 
Global Benzaldehyde Market Set to Witness an Uptick of USD 301.0 million by 2022
news
News of Observer - Dec 27, 2017 The global Benzaldehyde market has seen a potential growth over the past years. The Benzaldehyde industry is estimated to reach USD 301.0 million in 2022, growing at a CAGR of 3.20 percent between 2017 and 2022 according to this study.
over six months ago at http://www.military-technologies.net 
Dextran Market 2022 Challenger Is Threat To Face For Key Vendors Worldwide
news
MilTech - Dec 20, 2017 The Dextran Market provides detailed analysis of Market Overview, Market Drivers, Opportunities, Potential Application. Also Dextran Industry research report provides Emerging Market trends, Raw Materials Analysis, Manufacturing Process, regional ...
over six months ago at http://globenewswire.com 
Polydex Pharmaceuticals Ltd. Reports 3rd Quarter Financial Results
news
TORONTO, Dec. 15, 2017 -- Polydex Pharmaceuticals Limited is pleased to provide 3rd quarter financial results. Overcoming sales and production challenges, the Order Book remains robust and strong sales are anticipated ...
over six months ago at http://www.military-technologies.net 
Dextran Research on Market to 2022 Industry Trends, Market Overview and Top ...
news
MilTech - Dec 4, 2017 Pharmacosmos, Products Limited, Polydex Pharmaceuticals Ltd, Meito Sangyo Co Ltd, Herbon International Holdings, Dextran Market Segmentation by Product TypesPharmaceutical Grade, Agricultural Grade, Food Grade, Others,.
over six months ago at http://forextv.com 
dynaCERT Releases Verification of its Advances in Reefer Engine Performance
news
ForexTV.com - Nov 20, 2017 In particular, forward-looking information in this press release includes, but is not limited to future issuances of shares, approval by the TSX Venture Exchange.
over six months ago at http://nlrnews.com 
Polydex Pharmaceuticals Ltd. Shares Are Making Moves
news
Nelson Research - Dec 20, 2017 Investors have been buzzing over shares of Polydex Pharmaceuticals Ltd. as its price hit 1.29 at the end of the most recent trading day.
over six months ago at http://www.dispatchtribunal.com 
Polydex Pharmaceuticals Ltd. Scheduled to Post Quarterly Earnings on ...
patch News
Polydex Pharmaceuticals Ltd. will announce its earnings results on Wednesday, September 13th. Shares of Polydex Pharmaceuticals Ltd. opened at 1.29 on Monday. The company has a market cap of 4.38 million, ...

Latest Stories

Recently Published Stories

Revenue

Revenue Comparative Analysis
  Revenue 
      Polydex Pharmaceuticals Comparables 
Polydex Pharmaceuticals is currently under evaluation in revenue category among related companies. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of business and is important item when evaluating financial statements of a company. Revenues from a firm's main business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which given company operates.
Additionally take a look at Polydex Pharmaceuticals Hype Analysis, Polydex Pharmaceuticals Correlation and Polydex Pharmaceuticals Performance. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.